Repligen Co. (NASDAQ:RGEN) Stock Holdings Increased by Natixis Advisors L.P.

Natixis Advisors L.P. lifted its holdings in Repligen Co. (NASDAQ:RGEN) by 27.4% in the 4th quarter, HoldingsChannel reports. The firm owned 36,727 shares of the biotechnology company’s stock after purchasing an additional 7,892 shares during the quarter. Natixis Advisors L.P.’s holdings in Repligen were worth $6,603,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. New York Life Investment Management LLC grew its position in Repligen by 6.8% in the 4th quarter. New York Life Investment Management LLC now owns 5,904 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 375 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Repligen by 9.5% in the fourth quarter. Victory Capital Management Inc. now owns 21,271 shares of the biotechnology company’s stock valued at $3,825,000 after acquiring an additional 1,851 shares in the last quarter. Norden Group LLC increased its stake in shares of Repligen by 53.8% during the fourth quarter. Norden Group LLC now owns 2,142 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 749 shares during the period. Retirement Systems of Alabama raised its holdings in Repligen by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock worth $11,693,000 after purchasing an additional 288 shares in the last quarter. Finally, Alliance Wealth Advisors LLC UT lifted its position in Repligen by 4.9% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 2,460 shares of the biotechnology company’s stock worth $442,000 after purchasing an additional 114 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Down 0.4 %

Shares of RGEN opened at $164.89 on Friday. The business’s 50-day moving average price is $178.64 and its 200 day moving average price is $174.49. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $9.21 billion, a P/E ratio of 659.56, a P/E/G ratio of 5.58 and a beta of 1.03. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. During the same quarter in the previous year, the business earned $0.64 earnings per share. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. Analysts expect that Repligen Co. will post 1.46 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RGEN shares. JPMorgan Chase & Co. lowered their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Stifel Nicolaus lifted their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, KeyCorp upped their price target on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.